Coherus BioSciences (Coherus BioSciences) Total Inventories

: $62.6 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Coherus BioSciences's total inventories for the quarter that ended in Dec. 2023 was $62.6 Mil. Coherus BioSciences's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $64.7 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Coherus BioSciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-4.26.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Coherus BioSciences's Days Inventory for the three months ended in Dec. 2023 was 69.81.

Inventory Turnover measures how fast the company turns over its inventory within a year. Coherus BioSciences's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.31.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Coherus BioSciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.71.

Coherus BioSciences Total Inventories Historical Data

The historical data trend for Coherus BioSciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

9.81

44.23

37.64

38.79

62.61

Coherus BioSciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															38.79	49.41	63.99	66.78	62.61

Coherus BioSciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Coherus BioSciences (NAS:CHRS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Coherus BioSciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(117.748	+	0.75 * 260.522	+	0.5 * 62.605	-	823.029
-	0	-	0)	/	112.215
=	-4.26

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Coherus BioSciences's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	64.694	/	84.567	*	365 / 4
	=	69.81

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Coherus BioSciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	84.567	/	64.694
	=	1.31

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Coherus BioSciences's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	64.694	/	91.524
	=	0.71

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Coherus BioSciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (Coherus BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

8C5:Germany

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Executives

Dennis M Lanfear	director, officer: President and CEO	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell	officer: Chief Financial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael	officer: See Remarks	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider	officer: Chief Commercial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton	director	46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler	officer: Chief Scientific Officer	333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti	officer: Chief, Quality & Compliance	COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret	officer: Chief Financial Officer	ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper	director	150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson	director	ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas	director	1170 FAIRFAX STREET, BIRMINGHAM MI 48009